Other Clinical Assets

Cyclerion has deep expertise discovering and developing novel sGC stimulators for a wide variety of diseases.  As a CNS-focused company, we are out-licensing our non-CNS sGC stimulators for further development and commercialization. The most advanced in development are the oral, systemic sGC stimulators, praliciguat and olinciguat, which are described in greater detail below.  If you are interested in learning more, please email us at  partnering@cyclerion.com.

Praliciguat is an oral, once-daily, systemic sGC stimulator designed for the treatment of serious cardiovascular and renal diseases.  In preclinical studies, praliciguat demonstrated extensive distribution to key target tissues including adipose tissue, kidney, heart, and liver; the extensive, extra-vascular distribution of praliciguat has been confirmed in clinical studies. We believe this is fundamental to its potential to be a breakthrough therapy for cardiometabolic diseases characterized by adipose inflammation and metabolic dysfunction and associated with multi-organ etiology and involvement. Praliciguat has been licensed to Akebia Therapeutics for development in renal indications. 

Olinciguat is an oral, once-daily, vascular sGC stimulator that has been studied clinically in sickle cell disease. Olinciguat demonstrates broad pharmacology including effects on vascular function, inflammation, and fibrosis in multiple preclinical models, including those for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Clinical studies have demonstrated a well-tolerated dose range, dose-proportional pharmacokinetics, and target engagement. In the Phase 2 STRONG-SCD study, olinciguat was generally well tolerated across all dose levels but did not demonstrate adequate activity to support further internal clinical development in this indication. Olinciguat has potential for use in indications where the sGC mechanism has been clinically validated (eg, PAH and heart failure).